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T
he American College of Endocrinol-
ogyheldaConsensusConferencein
Washington, DC, on 21–22 July
2008 on the topic of pre-diabetes, orga-
nizedaroundaseriesofinterrelatedques-
tions. This is the third of a three-part
series summarizing presentations at the
conference.
What are the appropriate measures
to monitor pre-diabetes and its
treatment?
Peter Wilson (Boston, MA) reviewed Fra-
mingham data, with 30-year follow-up
now available, showing greater evidence
of adverse cardiovascular disease (CVD)
outcome with diabetes. It has been recog-
nized for some time that there are clus-
tered abnormalities within the metabolic
syndrome spectrum. BMI, triglycerides,
waist circumference, HDL cholesterol,
and fasting and 2-h insulin form one
group;fastingand2-hinsulinandglucose
another; and BMI and diastolic and sys-
tolic blood pressure levels a third (1),
with hyperinsulinemia a crucial factor in
many of these associations (2). Ho-
meostasis model assessment of insulin re-
sistance is associated with left ventricular
mass in women, though not in men (3).
Meigs and colleagues (4) showed evi-
dence that the coronary artery calcium
score is associated with insulin resistance
and with pre-diabetes. Metabolic syn-
drome is certainly related to outcome,
with CVD two to three times and diabetes
seven times more likely in those with 3–5
vs. 0–2 components of the syndrome. In
this analysis, the population-
attributable risk of metabolic syndrome
is approximately one-third that of CVD
and two-thirds that of diabetes for men,
withglucose(asexpected)themajorde-
terminant of diabetes risk among meta-
bolic syndrome variables. Population-
attributable risks of metabolic
syndrome were somewhat lower for
women. An alternative analysis divides
metabolic syndrome factors into none vs.
1–2 vs. 3–5, with a suggestion of in-
creased risk even in the intermediate
group and of markedly increased risk in
comparison with 3–5 vs. no metabolic
syndrome factors. If a measure of insulin
resistance is added to metabolic syn-
drome, both diabetes and CVD risks are
markedly augmented (5). There are argu-
ments against the use of metabolic syn-
drome, as its components are not all
equally powerful in Framingham predic-
tive models (6). Wilson also pointed out
that waist circumference and BMI ap-
pear equivalent in the analysis of this
population.
In the Framingham population, 20%
had impaired fasting glucose (IFG) only,
5% impaired glucose tolerance (IGT)
only, and 6% both, with likelihood of de-
veloping diabetes, based on fasting glu-
cose, 1.3% for those with neither, 4.3%
for those with IGT only, 9.2% for those
with IFG only, and 25.5% for those with
both. Wilson stated that diabetes predic-
tion based on age, sex, family history,
BMI,bloodpressure,andlipidsisasgood
as that based on the presence of IFG and
IGT, although using the actual glucose
levels improves prediction, and specu-
lated that it might be reasonable to deﬁne
pre-diabetes and diabetes based on com-
posite risk score, which he termed “a
weighted metabolic syndrome,” rather
than using glucose levels alone.
StevenHaffner(SanAntonio,TX)dis-
cussed “how and when pre-diabetes
progresses to diabetes.” Isolated IFG and
isolated IGT differ, with the latter more
associated with insulin resistance and in-
ﬂammation and the former with insulin
deﬁciency. In a population of individuals
with normal glucose tolerance, multi-
variate analysis shows that triglyceride,
HDL cholesterol, systolic blood pressure,
fasting glucose, and fasting insulin are
signiﬁcant markers of diabetes risk (7)—
exactly the components of the metabolic
syndrome as subsequently deﬁned.
Haffner reviewed analyses from San An-
tonio and Insulin Resistance Athero-
sclerosis Study datasets showing IGT
somewhat more strongly associated with
diabetes development than IFG. Both in-
sulin resistance and decreased insulin se-
cretion increase diabetes risk (8).
Inﬂammatory measures are strongly cor-
related with insulin resistance, including
C-reactive protein (CRP) and the leuko-
cyte count (9), with both CRP and plas-
minogen activator inhibitor (PAI)-1
quartile associated with diabetes risk
(10). Haffner analyzed the additional ef-
fect of metabolic syndrome in predicting
diabetes. Individuals with metabolic syn-
dromewithoutIGThada12%7-yearrisk
of diabetes, those with IGT without met-
abolic syndrome had a 25% risk, and
those with both had a 55% risk, suggest-
ing that they might be appropriate candi-
dates for pharmacologic intervention
(11). Another set of markers of diabetes
risk pertains to its association with he-
patic steatosis and to a progressive in-
crease in the likelihood of diabetes
associated with increasing alanine
transaminase (ALT) levels (12), both of
which are additive to the effect of CRP.
Thismightofferanotherparameteruseful
in determining whether pharmacologic
treatment would be indicated, with
Haffner suggesting that those individuals
whose annual likelihood of diabetes ex-
ceeded 8% might be candidates for such
an intervention. For such a group,
Haffner recommended use of IFG with a
glucose cutoff of 110 mg/dl, plus IGT and
metabolicsyndrome,presentin7%ofthe
population with a 10% annual diabetes
risk. Adding ALT somewhat improved
this. There is currently no information as
to whether serial measurements of glu-
cose levels would allow greater speciﬁc-
ity. Another reason for performing a
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taincasesofdiabetesbeforeinitiatingpre-
ventative treatment. A further approach
would be to develop models to determine
whichindividualswithpre-diabetesareat
greatest risk of diabetes complications
and, hence, would be better treatment
candidates.
Should we measure parameters
other than glucose and, if so, which
ones?
Larry Blonde (New Orleans, LA) dis-
cussedglycemicandnonglycemicparam-
eters to be monitored in pre-diabetic
patients and whether there is evidence of
an effect of glycemic variability on com-
plications of pre-diabetes. There were
17.9 million diagnosed and 5.7 million
undiagnosed people with diabetes in the
U.S. in 2007. IFG is present in 26% and
IGT in 15% of the population, and their
prevalence increases with age (13).
A1Cisassociatedwithfastingand2-h
postload glucose levels (14) and could be
considered for diabetes diagnosis, partic-
ularly given its relationship with progres-
sion of microvascular disease and given
the somewhat poor reproducibility of the
GTT, with fasting glucose having 6.4%
and 2-h glucose 16.7% variability (15).
A1C does not require fasting and has
good standardization, although nongly-
cemic factors affecting A1C should be
taken into account. In a study mainly of
type 1 diabetic patients, the correlation
between average glucose on continuous
glucose monitoring and A1C had an r
2 of
0.84 (16), although Blonde noted that it
appears likely that ethnic-speciﬁc values
needtobedevelopedforsuchananalysis.
IndividualswithA1C6%couldthenbe
said to have pre-diabetes, while A1C
7% on two occasions might be consid-
eredacceptableinconﬁrmingthediagno-
sis of diabetes (17). Home glucose
monitoring might also play a role in the
diagnosis of diabetes (18). Another po-
tential measure is the serum level of 1,5-
anhydroglucitol, a monosaccharide
similar to glucose ingested in the diet. Its
tubular reabsorption is prevented by gly-
cosuria, so higher levels equate to lower
glycemia.
Blonde suggested several other inter-
esting parameters that might be moni-
tored. 25-hydroxy-vitamin D may be
associated with risk of developing diabe-
tes (19–21). Oxidative stress has been
thesubjectofmuchinvestigation(22).In-
termittent hyperglycemia may cause this
byactivatingproteinkinaseC(PKC)(23),
and there is evidence that postprandial
glycemia is associated with elevations in
prostaglandin F2 (24,25), a potential
measure of this process. Advanced glyca-
tion end products may be involved in
complications of pre-diabetes, and there
is evidence that skin advanced glycation
end product levels can be measured from
small-punch biopsy sites (26). In the fu-
ture, Blonde speculated, genetic markers
such as TCF7L2 will also be assessed in
determining diabetes risk.
Can society afford the costs of
treating or not treating the pre-
diabetes state?
William Herman (Ann Arbor, MI) dis-
cussed costs of type 2 diabetes and ap-
proachestoassessingcost-effectivenessof
diabetes prevention, suggesting it to be a
highly useful endeavor. Taking into ac-
count diabetes, its complications, and
general medical care, the annual direct
cost of diabetes is 116 billion USD, with
an additional indirect cost of illness, dis-
ability, and premature mortality totaling
58 billion USD (27). Of these amounts,
56% is incurred by individuals aged 65
years and 35% by those aged 45–64
years. Fifty percent of direct costs are in
hospital, 24% for pharmaceutical prod-
ucts and supplies, 20% for outpatient
care, and 6% for nursing home care.
“We’re spending a lot of the money on
older people and a lot of it is driven by
late, chronic complications,” Herman
summarized. Macrovascular disease con-
tributes 52% of costs, but as diabetes
duration increases, the costs of micro-
vascular complications, particularly of
diabetic nephropathy, become more im-
portant (28). Cost-effectiveness may be
calculated as the ratio between the differ-
ence in cost of intervention versus usual
care to the difference in health outcomes
associated with intervention versus usual
care. Cost-utility analysis includes costs
of the interventions and outcomes, ex-
pressingoutcomesinquality-adjustedlife
years(QALYs).Thus,perfecthealthmight
be assigned a utility of 1.0, pre-diabetes
0.8, diabetes 0.6, diabetes with complica-
tions 0.4, and death 0.0. Assuming the
usual cost of pre-diabetes to be 800 USD
andthatofpre-diabeteswithintervention
1,600 USD annually, and annual costs of
uncomplicated and complicated diabetes
of 1,800 and 3,000 USD, respectively,
Herman presented an analysis of a Diabe-
tes Prevention Program–type interven-
tion that, on average, delayed diabetes
onset by 5 years (3.4 years with met-
formin and 11.1 years with lifestyle mod-
iﬁcation). If complications began an
average of 10 years after diagnosis, Her-
man calculated that, viewed over a 30-
year period, standard and intervention
approaches beginning with pre-diabetes
cost 56,000 and 57,000 USD, respec-
tively; however, with outcomes of 18 vs.
20 QALYs, the intervention approach
thus costs 500 USD per QALY (29), rep-
resenting a very inexpensive approach
compared with typical intervention costs
of well over 10,000–20,000 USD per
QALY. “In essence,” Herman said, “the
costs of pre-diabetes will be paid later if
we don’t do anything today.”
What future research is needed to
further clarify the diagnosis and
management of the pre-diabetes
state?
Gerald Shulman (New Haven, CT) dis-
cussed the role of skeletal muscle in the
pathogenesis of type 2 diabetes and the
metabolic syndrome. Using nuclear mag-
netic resonance (NMR) spectroscopy, it is
possible to noninvasively follow intracel-
lular metabolism. This approach allows
measurement of incremental change in
muscle glycogen in normal versus type
2 diabetic individuals (30), showing a
profound defect in muscle glycogen
synthesis. Assessment of the rate-
controlling step comparing uptake via
GLUT4, hexokinase activity causing
glucose-6-phosphate (G6P) formation,
and glycogen synthase for glycogen for-
mation (31) shows the defect to be in the
glucose transport step. Hexokinase and
glycogen synthase might then, Shulman
commented, be poor pharmacologic tar-
gets. Use of calf-muscle proton NMR to
measure intramyocellular fat shows this
to be the best predictor of insulin resis-
tance (32). The Randle hypothesis pre-
dicts that fat-induced insulin resistance
involves competition between fatty acids
andglucoseinuptakebytheinhibitionby
phosphofructokinasetoincreaseG6Plev-
els (33), but phosphate NMR measure-
ment of G6P (34) and carbon NMR to
measureglucoseshowsthatfattyacidsdi-
rectly inhibit skeletal muscle GLUT4
(35).Fattyacidsabolishinsulinactivation
of phosphatidyl inositol-3-kinase (34).
Elevated plasma free fatty acids increase
intracellular diacyl glycerol, leading to ki-
nase C activation, which causes insulin
receptor substrate-1 serine phosphoryla-
tion to reduce phosphatidyl inositol-3-
kinase and thereby decrease GLUT4
activity. Targets to block this include
Bloomgarden
DIABETES CARE, VOLUME 31, NUMBER 12, DECEMBER 2008 2405PKC, acetyl-CoA carboxylase, and un-
coupling protein-3. In the liver, a similar
pathway of fatty acid–induced insulin re-
sistance via increased diacyl glycerol
causes PKC-ε activation (36). There are,
then, multiple potential sites that ratio-
nally could be exploited in developing
interventions. In mice lacking adipose
tissue, there is severe muscle and liver
insulin resistance associated with dou-
bling of both liver and muscle fatty acyl
CoA, all normalized by adipose tissue
transplantation (37). “It’s not a question
of how much fat we have,” Shulman
commented. “It’s really how the fat is dis-
tributed.” The important common mech-
anism of treatments, then, involves
reduction of intracellular fat in muscle
and liver, a potential mechanism of effect
of the thiazolidinediones (TZDs).
Shulman reviewed studies of individ-
uals with lipodystrophy in which leptin
administration for 6 months normalized
fasting glucose, with improvement in in-
sulin-stimulated muscle glucose uptake
(38). Proton NMR in these patients dem-
onstrated that liver and muscle fat were
markedly reduced by treatment. In a less
extreme example, weight loss with a
1,200-caloriedietinobesetype2diabetic
patientsdecreasedfastingglucoseandhe-
patic triglyceride concentration (from 10
to 2%), associated with reduction of
hepatic glucose production and near-
normalization of hepatic insulin sensitiv-
ity, though without changing circulating
cytokines(39).Intracellularfatanddiacyl
glycerol appear to underlie these abnor-
malities; fat cells that “hold onto fat” are
the answer, as shown with the “ﬁt fat”
phenotype. Mitochondrial abnormalities,
eitheracquiredorinherited,mayunderlie
some of these conditions.
Shulman asked whether the meta-
bolic syndrome is derived from such
states. In a study of insulin sensitivity
among 400 lean, healthy, 20-year-old in-
dividuals,
13carbon NMR was used to
measure glycogen, proton NMR to mea-
sure intracellular fat, and magnetic reso-
nance imaging to quantitate visceral fat
(40). There were no differences in intra-
abdominal fat between insulin-sensitive
and insulin-resistant individuals, but in-
sulin levels after a carbohydrate load
markedly differed, with the insulin-
resistant group forming less muscle gly-
cogen and markedly more hepatic
triglyceride, increased de novo lipogene-
sis, and an association with increased cir-
culating triglyceride and reduced HDL
cholesterol levels. These abnormalities
normalize with exercise (41). Shulman
pointed out that IFG and IGT may have
different determinants, with fasting hy-
perglycemia caused by increased hepatic
gluconeogenesis while postload hyper-
glycemia reﬂects a reduction in glucose
uptake by liver and muscle.
Jack Leahy (Burlington, VT) dis-
cussed the -cell. Each person has 1
million pancreatic islets, which he de-
scribed as multicellular organelles with
complexinteractionsofnutrients,growth
factors, neurotransmitters, and incretins
regulated by numerous cellular receptors
and nuclear receptor transcription fac-
tors.Thecurvilinearrelationshipbetween
insulin action and insulin secretion sug-
gests that declining -cell function from
an already decreased baseline underlies
worsening glucose tolerance among ini-
tially insulin-resistant individuals. He
cited a just-published study of healthy in-
dividuals with normal glucose tolerance
who underwent hemipancreatectomy to
become pancreas donors between 1997–
2003, 43% of whom had pre-diabetes or
diabetes at follow-up (42).
Alargenumberoftype2diabetessus-
ceptibility genes that regulate the -cell
have been discovered (TCF2, IGFBP2,
WFS1, CDKAL1, SLC30A8, CDKN2A/B,
HHEX/IDE, TCF7L2, KCNJ11, CDC123-
CAMK1D, THADA, and NOTCH2) while
fewersusceptibilitygeneshavebeeniden-
tiﬁed affecting insulin sensitivity or with
as-yet unidentiﬁed effects (43–45).
“We’re really still in the stage of just cata-
loging,” Leahy commented, pointing out
that there are “many years of hard work”
to better understand these factors.
Whenthe-cellbeginstodecompen-
sate, entering a stage of -cell failure,
-cell mass decreases up to 40% in pre-
diabetesand60%indiabetes.Theacute
insulinresponsedecreasesinpre-diabetes
and to an even greater extent in diabetes
(46).Autopsystudiesshowthatbothpre-
diabetes and diabetes are associated with
reductions in -cell mass (47). There is,
however,evidencethatanumberoftreat-
mentsallowthe-celltorecoverfunction
in type 2 diabetes: insulin administration
(48), -cell rest using diazoxide (49), so-
matostatin (50), TZDs (which also poten-
tially reduce fatty acid-induced -cell
toxicity, as has also been shown with
acipimox [51]), administration of GLP-1,
andanti-inﬂammatorytreatmentusingan
interleukin-1 receptor antagonist (52).
-Celldysfunction,then,maybearevers-
ible phenomenon involving increased ap-
optosis, amyloid deposition, lipotoxicity,
oxidative stress, inﬂammation, or im-
paired incretin effect (53). Leahy ampli-
ﬁed Shulman’s comment on the
difference between IGT and IFG, noting
thatIFGparticularlyreﬂectshepaticinsu-
linresistancesuchthat-celldysfunction
may be less of a factor, whereas IGT pri-
marilyrepresentsamismatchbetweenin-
sulin response and need, with failure of
postprandial glucose clearance in part
due to insulin resistance but also involv-
ing -cell dysfunction and potentially be-
ing caused by excess glucagon action.
Theprecisepathogenesisofthe-cell
defects is, however, unknown, and the
concept that there is a pathophysiological
difference between IFG and IGT should
be recognized as speculative. Further-
more, -cell function represents a num-
ber of independent functional and mass-
related contributions, so there may be no
simple test that can be said to measure
-cell function, with the integrated insu-
linresponsetoanoralorintravenousglu-
cose challenge not likely to represent the
same function as the individual compo-
nents of this response. Whether -cell
mass is the major determinant of insulin
response is actually unknown, and there
is certainly no evidence that durability of
response to a given treatment will be de-
pendent on its effect on -cell mass or
that treatment of pre-diabetes should be
focused primarily on the -cell. Ap-
proaches to measurement of -cell func-
tion include homeostasis model
assessment of -cell function, the proin-
sulin-to-insulin ratio, measurement of in-
sulin and C-peptide responses to oral or
intravenous glucose, the frequently sam-
pled intravenous GTT, and application of
the related “minimal model” to meals,
static or graded hyperglycemic clamps,
the disposition index, and measurement
of pulsatile insulin secretion or of the en-
trainment of pulsatile secretion. Many of
these measures are abnormal in relatives
oftype2diabetesindividuals,butitisnot
clear that any of these tests are adequately
speciﬁc or sensitive to understand ab-
normalities of type 2 diabetes and
pre-diabetes. Positron emission tomog-
raphy–based imaging of
11C-dihydrotet-
rabenazine bound to type 2 vesicular
monoamine transporters in a baboon
model has been demonstrated (54), sug-
gesting that it may be possible to develop
approaches for noninvasive -cell mass
assessment.Geneexpressionstudiesofis-
lets obtained at autopsy from individuals
with and without type 2 diabetes (55)
may allow further information about
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ising directions of research include stud-
ies of incretin action, with GLP-1 having
effects on -cell proliferation, apoptosis,
and mass (56), and of the TZDs, although
one need not suggest that these agents are
directly beneﬁcial for the -cell, as lower-
ing the insulin requirement can allow de-
ﬁcient insulin secretory function to
become adequate.
George Alberti (London, UK) dis-
cussed future research needed to further
clarify the diagnosis and management of
the pre-diabetic state. He noted that there
were 309 million individuals with IGT
worldwide in 2007, and there is a projec-
tion that there will be 419 million by
2025. Notions of pre-diabetes suggested
inthe1950swerereplacedin1980bythe
functionally similar recommendation of
the World Health Organization that sta-
tistical risk classes be used, but the
concept was reintroduced in 2002 by De-
partment of Health and Human Services
Secretary Tommy Thompson as an ap-
proach describing the conditions of IGT
and IFG in a fashion that would commu-
nicate their high risk to the public. As
presently deﬁned, pre-diabetes may,
however, omit other individuals at
equally high risk, such as those with
strongly positive family history, obesity,
hypertension, dyslipidemia, CVD, meta-
bolicsyndrome,orahistoryofgestational
diabetes mellitus who do not have abnor-
malities of glucose tolerance by current
deﬁnitions. Furthermore, Alberti pointed
out that 30% of individuals with pre-
diabetes as deﬁned by IGT or IFG will
revert to normal glucose tolerance, and
over their lifetimes only half will develop
diabetes. This led him to question
whether this group alone is deserving of
the term. Indeed, the relative weights of
the different risk factors for lifetime risk
of diabetes need to be better clariﬁed.
The recommended diagnostic criteria
have changed over time. In 1979 and
1985, the National Diabetes Data Group
and the World Health Organization sug-
gested that IGT be deﬁned by fasting
plasma glucose between 140 and 144
mg/dl and 2-h postload glucose of 140–
198 and 144–196 mg/dl, respectively. In
1985, fasting glucose 140 mg/dl and
2-h glucose of 140–198 mg/dl were sug-
gested, and in 1997 the fasting glucose
criterion was changed to a glucose of
110–125 mg/dl, introducing the concept
of IFG. In 2003, the ADA suggested the
lower limit of IFG be 100 mg/dl.
The purpose of labeling a person as
pre-diabetic,Albertisuggested,shouldbe
toidentifythoseathighriskofdeveloping
diabetesandCVD.Hereviewedstudiesin
Mauritius in 1987, 1992, and 1998. The
population in the island comprises three
ethnic groups—Asian Indians, blacks
(Creoles), and Chinese—that together
constitute two-thirds of the world’s pop-
ulation, making this an excellent model.
Those with IGT alone or IFG alone had
3.1–3.2 times increased risk of diabetes
over 10 years, while those having both
had nearly a ﬁvefold increase in diabetes
risk,leadingAlbertitoemphasizetheuse-
fulness of the GTT. Over a decade, one-
third of those with IFG or IGT became
normal glucose tolerant, one-third pro-
gressedtodiabetes,andone-thirdcontin-
ued to have pre-diabetes, although the
frequency of progression appears to be
worsening in recent studies (57). The
long-termoutcomeand,crucially,theuse
of glucose tolerance information to rec-
ommend treatments are being explored.
The actual cut points used may not,
Alberti noted, be correct. The upper limit
isthediabetescriterion,whiletheloweris
an arbitrary ﬁgure. Those with IGT at lev-
els exceeding 170 mg/dl fasting glucose
probably have considerably greater risk
than those with 2-h glucose levels closer
to 140 mg/dl. The IFG criteria based on
equalizing the numbers of individuals
with IFG and IGT do not appear to be
an evidence-based recommendation, and
it is more accurate to understand that
there is a continuum of risk within the
glucose levels currently considered to
represent pre-diabetes. First-phase insu-
lin secretion becomes abnormal begin-
ning at a fasting glucose of 95 mg/dl,
Albertistated,andhesuggestedthatthere
is no real glucose cut point for CVD risk
and that it is not clear why the risk of
elevated 2-h glucose exceeds that of ele-
vated fasting glucose.
One might, Alberti suggested, simply
change the terminology and state that in-
dividuals with IFG or IGT in fact have
diabetes, as has been suggested by the
ﬁndingofretinopathywithinpopulations
of individuals with pre-diabetes. How-
ever, it would be rather complicated to
abruptly double the number of individu-
als with diagnosed diabetes. What, he
asked, is the pathophysiological basis for
pre-diabetes? Islet abnormalities, insulin
resistance, and genetic polymorphisms
have been found, and the apparent dis-
tinction that IGT represents decreased
glucose disposal while IFG is a state of
glucose overproduction may be of im-
portance. How, he asked, should we
endeavor to detect individuals with
pre-diabetes? This becomes an issue par-
ticularly if the GTT is not routinely per-
formed, he stated, suggesting that it may
be useful to develop screening ap-
proaches to determine appropriate candi-
dates for the GTT, perhaps screening
individuals based on obesity, family his-
tory or ethnic group, hypertension, dys-
lipidemia, or CVD. A possible stepwise
approach is to start with a questionnaire
such as that described by Tuomilehto (as
summarized in ref. 58), perhaps supple-
mented by waist circumference measure-
ment, followed ﬁrst by fasting glucose
measurement and then the GTT. Al-
though A1C might be measured rather
than performing a GTT, Alberti preferred
the latter, suggesting that development of
a home kit with oral glucose and test
strips might be useful in population
screening. An interesting study would
compare the natural history of pre-
diabetic individuals found by screening,
pre-diabeticindividualsfoundbyhistory,
and individuals having diabetes at initial
presentation.
Finally, Alberti asked whether pre-
diabetesshouldbetreated,andifso,how?
Recalling that one-third revert to normal
glucosetolerance,heaskedwhetherasin-
gle abnormal GTT should be repeated.
Wedonotknowwhethertheaimoftreat-
mentshouldberestorationofnormalglu-
cose tolerance or prevention of diabetes.
Prevention of CVD will probably, he sug-
gested, be impossible to ascertain and
may not be an appropriate goal for a state
deﬁned by glycemia, and he noted that
statins would be more likely than met-
formin to have a beneﬁt in this regard. At
present, he suggested that use of acarbose
and metformin might be considered, not-
ing that “we don’t have the data” to rec-
ommend treatment with other agents.
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